Boundless Bio to merge with Serapha Bio
Boundless Bio entered into a merger agreement with Serapha Bio to combine in an all-stock deal. Shareholder approval is required to complete the reorganization.
View filing at SEC.gov →2 most recent filings and news items mentioning BBIO. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/BBIO/news?limit=20"
Pull BBIO filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayBoundless Bio entered into a merger agreement with Serapha Bio to combine in an all-stock deal. Shareholder approval is required to complete the reorganization.
View filing at SEC.gov →BridgeBio announced FDA acceptance of its New Drug Application for BBP-418 to treat LGMD2I/R9, a rare genetic muscular dystrophy, with a Priority Review designation and potential November 2026 approval. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and the first a
View filing at SEC.gov →